Enlivex (ENLV) Change in Account Payables (2013 - 2025)
Enlivex (ENLV) posted quarterly Change in Account Payables of $3.4 million for Q4 2025, up 377.47% year-over-year from $719000.0 in Q4 2024, and up 2155.69% quarter-over-quarter from -$167000.0 in Q3 2025.
Enlivex (ENLV) Change in Account Payables (2013 - 2025) Analysis & Trends
Enlivex's Change in Account Payables history runs 13 years deep, the most recent figure standing at $3.4 million for Q4 2025.
- In Q4 2025, Change in Account Payables rose 377.47% year-over-year to $3.4 million; the TTM figure through Dec 2025 stood at $3.0 million (up 18831.25% YoY), while the FY2025 annual figure was $3.0 million, up 18831.25% from the prior year.
- Change in Account Payables for Q4 2025 stood at $3.4 million, up from -$167000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $3.4 million in Q4 2025, with the low at -$914000.0 in Q3 2023.
- The 5-year median for Change in Account Payables is -$46000.0 (2021), against an average of $173500.0.
- The sharpest annual moves came in 2022 and 2024: Change in Account Payables sank 442.08% in 2022, then soared 2078.79% in 2024.
- Enlivex's Change in Account Payables stood at -$154000.0 in 2021, then jumped by 742.21% to $989000.0 in 2022, then plunged by 96.66% to $33000.0 in 2023, then jumped by 2078.79% to $719000.0 in 2024, then surged by 377.47% to $3.4 million in 2025.
- Business Quant data shows ENLV's Change in Account Payables at $3.4 million in Q4 2025, -$167000.0 in Q3 2025, and $9000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | 3.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.43 Mn |
| Dec 31, 2025 | 3.43 Mn |
| Sep 30, 2025 | -167,000.00 |
| Sep 30, 2025 | -167,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Mar 31, 2025 | -278,000.00 |
| Mar 31, 2025 | -278,000.00 |
| Dec 31, 2024 | 719,000.00 |
| Dec 31, 2024 | 719,000.00 |
| Sep 30, 2024 | -211,000.00 |
| Sep 30, 2024 | -211,000.00 |
| Jun 30, 2024 | -341,000.00 |
| Jun 30, 2024 | -341,000.00 |
| Mar 31, 2024 | -183,000.00 |
| Mar 31, 2024 | -183,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Sep 30, 2023 | -914,000.00 |
| Sep 30, 2023 | -914,000.00 |